Mirtazapine is an atypical antidepressant and is used primarily for the treatment of a major depressive disorder
Over 32,000 AT&T outages were reported by customers about 4 a
Dizziness, drowsiness, lightheadedness, increased appetite, weight gain, dry mouth, or constipation may occur
Mirtazapine (Remeron, Remeron SolTab) is a generic prescription medication used to treat depression in adults
It's taken by mouth once daily, typically at nighttime because it
Generic name: mirtazapine [ mir-TAZ-a-peen ] Brand names: Remeron, Remeron SolTab
How it works Mirtazapine may be used to treat depression
Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994
Usual Adult Dose for Depression
Taking mirtazapine with other medicines and herbal supplements
swollen glands
The most common side effects of mirtazapine include drowsiness, dry mouth, weight gain, increased appetite, increased cholesterol and triglycerides, dizziness, constipation, confusion, and abnormal dreams
How to take it
Generic mirtazapine is covered by most Medicare and insurance plans, but some pharmacy coupons or cash prices may be lower
Low white blood cell count ( neutropenia) Postmarketing side effects of mirtazapine reported include: Severe skin reactions: Stevens-Johnson syndrome
At the same time, its sleep-promoting effects in patients with major depressive disorder (MDD) are relatively unclear
This medicine is available only with your doctor's prescription
3
For example, if you take a dose of 30 milligrams (mg) of mirtazapine, you may be at a higher risk of side effects than someone taking a 7
risk of profound CNS and resp
It is also a potent antagonist of 5-HT 2 and 5-HT 3 serotonin receptors and H 1 histamine receptors and a moderate peripheral alpha 1 Uses for mirtazapine
Severe nausea/vomiting/diarrhea
Feeling sleepy
, and received FDA approval in 1997 for the treatment of major depressive disorder
Xanax has an average rating of 8
Media Inquiries 619